August 9, 2022
Daiichi Sankyo and partner AstraZeneca’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) won US FDA approval for the treatment of certain HER2 low metastatic breast cancer patients, the companies said on August 5. The drug received the green light for the...read more